Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals

CompletedOBSERVATIONAL

Enrollment

30,430

Participants

Timeline

Start Date

October 1, 2016

Primary Completion Date

June 1, 2017

Study Completion Date

June 1, 2017

Conditions

Neuromuscular Blockade

Interventions

DRUG

Rocuronium

DRUG

Succinylcholine

DRUG

Cisatracurium

DRUG

Mivacurium

DEVICE

Objective neuromuscular monitoring (acceleromyography)

DRUG

Sugammadex

DRUG

Neostigmine

Trial Locations (1)

Herlev Hospital, Herlev

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Jakob Louis Thomsen

OTHER

NCT02914119 - Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals | Biotech Hunter | Biotech Hunter